Naloxone Behind-the-Counter? Petition Could Help Push Action
This article was originally published in RPM Report
Executive Summary
The idea of “behind-the-counter” may be behind the times, but a request to put naloxone there could help push FDA’s existing interest in expanding access to the overdose antidote.
You may also be interested in...
FDA’s ‘Access’ Challenge Highlighted At Naloxone Meeting
‘Behind-the-counter’ placement of opioid overdose treatment doesn’t resonate with agency, even as it wants to broaden availability.
Naloxone Could Go OTC
A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.
CDER Director Sees Behind-The-Counter Switches As Best Bet
FDA drug center chief Janet Woodcock says behind-the-counter switches would be the most effective method to make Rx drugs available without prescriptions, particularly to help treat chronic conditions.